Ceftazidime-Avibactam Renal Dosing
For adult patients with normal renal function (CrCl ≥51 mL/min), administer ceftazidime-avibactam 2.5 g (ceftazidime 2 g/avibactam 0.5 g) IV every 8 hours over 2 hours; dose adjustments are required for renal impairment based on creatinine clearance, with specific reduced doses and extended intervals for moderate (CrCl 31-50 mL/min), mild-to-moderate (CrCl 16-30 mL/min), and severe impairment (CrCl 6-15 mL/min), and post-dialysis dosing for hemodialysis patients.
Dosing by Renal Function
Normal Renal Function (CrCl ≥51 mL/min)
- Standard dose: 2.5 g (2 g/0.5 g) IV every 8 hours over 2 hours 1
- This maintains optimal pharmacokinetic/pharmacodynamic (PK/PD) targets of ≥50% fT>MIC for ceftazidime and ≥50% fT>1 mg/L for avibactam 2, 3
Moderate Renal Impairment (CrCl 31-50 mL/min)
- Adjusted dose: 1.25 g (1 g/0.25 g) IV every 8 hours over 2 hours 1
- Maintains adequate PK/PD target attainment under conventional targets 4, 5
Mild-to-Moderate Renal Impairment (CrCl 16-30 mL/min)
- Adjusted dose: 0.94 g (0.75 g/0.19 g) IV every 12 hours over 2 hours 1
- Alternative regimens with extended infusion (3-4 hours) may improve target attainment 4
Severe Renal Impairment (CrCl 6-15 mL/min)
- Adjusted dose: 0.94 g (0.75 g/0.19 g) IV every 24 hours over 2 hours 1
- Critical consideration: Recent evidence suggests standard renal-adjusted doses for CrCl ≤10 mL/min may be insufficient, achieving only T>MIC <60% and Cmin/MIC <0.35 2
End-Stage Renal Disease on Intermittent Hemodialysis
- Loading dose: 2.5 g (2 g/0.5 g) single dose
- Maintenance: 0.94 g (0.75 g/0.19 g) IV every 48 hours over 2 hours, administered after each hemodialysis session 1
- Alternative post-HD regimen: 0.94 g-0.94 g-2.5 g maintains ≥90% PTA for ceftazidime throughout the week, though avibactam may fall slightly below target on the final day 6
Critical Clinical Considerations
Severe Infections and Augmented Renal Clearance
For critically ill patients with normal or augmented renal clearance (CrCl >120 mL/min) and severe infections, the standard q8h regimen may be inadequate 3. Consider:
- Extended infusion: Prolong infusion to 3-4 hours to achieve 100% fT≥MIC targets 3
- Continuous infusion: May be necessary for 100% fT≥4×MIC targets in the most severe cases 3
- The q6h regimen provides higher joint PTA than q8h dosing in preserved renal function 5
Renal Dose Adjustment and Mortality Risk
A critical pitfall: Renal dose reduction has been independently associated with increased mortality (HR 4.47,95% CI 1.09-18.03) in patients with KPC-producing Klebsiella pneumoniae bloodstream infections 7. This suggests that recommended renal-adjusted doses may provide inadequate drug exposure. When treating severe infections in patients with renal impairment:
- Monitor clinical response closely
- Consider therapeutic drug monitoring (TDM) if available
- For CrCl ≤10 mL/min, consider shortening dosing intervals rather than reducing doses further 2
Infusion Duration Matters
- Standard: 2-hour infusion is recommended across all renal function strata 1
- Severe infections: Extend to 3-4 hours for patients with normal renal function to optimize PK/PD target attainment 8, 3
- Do not shorten: 1-hour infusions reduce target attainment and should be avoided 9
Loading Dose Considerations
- Loading doses are not affected by renal function and should be given at full dose when indicated 10
- For severe infections (sepsis, bacteremia, pneumonia), consider a loading dose of 2.5 g before initiating maintenance dosing 10
Monitoring and Safety
Electrolyte monitoring is essential:
- Avibactam can cause severe, refractory hypokalemia, particularly in elderly patients or those with renal dysfunction 11
- Monitor serum potassium closely and supplement aggressively as needed
- Consider spironolactone if hypokalemia persists despite supplementation 11
Neurotoxicity risk:
- Ceftazidime Cmin >80 mg/L is associated with neurotoxicity risk 5
- Risk remains low with standard renal-adjusted dosing but increases with higher doses 6
- TDM is recommended for patients with fluctuating renal function or severe infections 8
Hepatic Dysfunction
No dose adjustment is required for hepatic impairment, provided renal function is preserved 1
Practical Algorithm for Dose Selection
- Calculate CrCl using Cockcroft-Gault equation (use actual body weight) 1
- Select base regimen according to CrCl category above
- Adjust for severity:
- Severe infection + normal renal function → extend infusion to 3-4 hours
- Severe infection + CrCl ≤10 mL/min → consider shortening interval rather than further dose reduction
- For hemodialysis patients: Always dose after dialysis session 1
- Monitor: Potassium levels (at least every 2-3 days), clinical response, and consider TDM if available
This renal-stratified approach balances practical administration with PK/PD optimization while minimizing toxicity risk across the spectrum of renal function 4, 5.